Drug details

Retacrit (epoetin alfa-epbx injection)

type of Erythropoiesis-Stimulating Agents

Retacrit (epoetin alfa-epbx) Injection is an erythropoiesis-stimulating agent (ESA) indicated for treatment of anemia due to chronic kidney disease (CKD) in patients on dialysis and not on dialysis; zidovudine in patients with HIV-infection; the effects of concomitant myelosuppressive chemotherapy, and upon initiation, there is a minimum of two additional months of planned chemotherapy; and reduction of allogeneic RBC transfusions in patients undergoing elective, noncardiac, nonvascular surgery.

The drug is often used to treat HIV .

This drug may have the following side effects:
  • hives,
  • difficulty breathing,
  • swelling of your face, lips, tongue, or throat,
  • nausea,
  • fever,
  • pain spreading to your jaw or shoulder,
  • fluttering in your chest,
  • seizure,
  • blurred vision,
  • pounding in your neck or ears,
  • constipation,
  • dry mouth,
  • wheezing,
  • fainting,
  • sweating,
  • chest pain or pressure,
  • unusual tiredness,
  • sore throat,
  • burning eyes,
  • skin pain,
  • red or purple skin rash with blistering and peeling,
  • increased thirst,
  • increased urination,
  • fruity breath odor,
  • irregular heartbeats,
  • sudden numbness or weakness (especially on one side of the body),
  • slurred speech,
  • problems with vision or balance,
  • nosebleeds
  • leg cramps,
  • numbness or tingling,
  • severe dizziness,
  • muscle weakness or limp feeling,
  • sudden severe headache,
  • anxiety, and
  • rapid pulse,
  • pain, swelling, warmth, redness, cold feeling, pale appearance of an arm or leg,
The following drugs are related to Retacrit, either as a replacement or used together:
  • Triferic AVNU (ferric pyrophosphate citrate injection)
  • Folic Acid (folic acid)
  • Glofil-125 (sodium iothalamate i-125 injection solution)